Clin Cancer Res: CLL patients can also benefit from BTK inhibition when they deactivate Vinacra.

Venetoclax is currently the only approved Bcl-2 selective inhibitor in the world for the treatment of chronic lymphocytic leukemia (CLL) or small lymphocyte lymphoma (SLL).
in January, Vinacra filed a domestic listing.
Venecra-based treatment is the standard treatment for first-line recurrence/refractive chronic lymphocytic leukemia.
patient management after the discontinuation of Vinacra is still irregular and little known.
to address this problem, Mato et al. conducted a large international study, recruiting a queue of 326 patients who had discontinued Vinacra and continued follow-up treatment.
the main endpoints are the Total Mitigation Rate (ORR) and the No Progress Survival Rate.
results: 4% and 96% of CLL patients discontinued in Vinacra, respectively, in the first-line and recurrence/difficulty background.
patients received three treatments prior to the treatment of Vinacra (median): 40% of BTKi primary treatment (130) and 81% of patients for idelalisib (263).
84% (44) of THE ORR treated with BTKi in patients with BTKi primary treatment, compared with 54% (30) of PATIENTs treated with BTKi.
this study demonstrates that new drug exposure and venekra discontinuation reasons need to be taken into account when selecting therapeutic drugs after discontinuation of Vinacra.
Conclusion: For patients with BTK primary treatment, high ORR and long-lasting remission can be obtained with covalent combination BTKIs treatment.
BTKi resistance has developed in patients treated with BTKi, the effect of covalent BTK inhibition is minimal.
veincra retires, the use of PI3Kis will not provide lasting relief.
in general, cell therapy after discontinuation of Vinakra may be the most effective strategy for btKi-primary or previously used patients.
.